#ESCCongress – [Abstract Only] Randomized trial: Cardiovascular and renal outcomes with Empagliflozin in heart failure

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure – New England Journal of Medicine

Commentaries: EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF – TCTMD AND EMPEROR-Reduced meets primary endpoint in heart failure with reduced ejection fraction – European Society of Cardiology AND Empagliflozin Outcome Trial in Patients With Chronic Heart Failure and a Reduced Ejection Fraction – EMPEROR-Reduced – American College of Cardiology

Related study: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction – New England Journal of Medicine

Commentary on Twitter

Original Article: Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced Trial) #ESCCongress

— NEJM (@NEJM) August 29, 2020